Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome

Rheumatology

Volumn 46, Issue 6, 2007, Pages 907-910

  Christodoulou, C ^a   Sangle, S ^a   D'Cruz, David P ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid syndrome; Atherosclerosis; Intima media thickness; Stenotic lesions; Vasculopathy

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARYLDIALKYLPHOSPHATASE; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; FC RECEPTOR; FOLIC ACID; HEPARIN; HIGH DENSITY LIPOPROTEIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY; VITAMIN B GROUP; WARFARIN;

ANGIOCARDIOGRAPHY; ANKLE BRACHIAL INDEX; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY INTIMA PROLIFERATION; ARTERY OCCLUSION; ARTERY THROMBOSIS; ATHEROSCLEROSIS; BLOOD VESSEL OCCLUSION; CELIAC ARTERY STENOSIS; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; CORONARY STENT; DIABETES MELLITUS; FETUS WASTAGE; HEART DEATH; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; KIDNEY ARTERY STENOSIS; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESTENOSIS; REVIEW; RISK ASSESSMENT; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM;

ANTIPHOSPHOLIPID SYNDROME; ARTERIAL OCCLUSIVE DISEASES; ATHEROSCLEROSIS; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC;

EID: 34447312169     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem040     Document Type: Review

References (59)

1. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999;42:1309-11.
2. Urowitz MB, Bookman AM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of SLE. Am J Med 1976;60:221-5.
3. Doherty NE, Siegel RJ. Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 1985;110:1257.
4. Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus 1996;5:442-7.
5. Matsuura E, Koike T. Accelerated atheroma and anti-β2-glycoprotein I antibodies. Lupus 2000;9:210-6.
6. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000;9:170-5.
7. Sherer Y, Tenenbaum A, Praprotnik S et al. Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-1, and oxidised LDL antibodies. Cardiology 2001;95:20-4.
8. Vaarala O, Manttari M, Manninem V et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995;91;23-7.
9. Steinbrecher UP, Parthasarathy S, Leake DS, Witzturn JL, Steinberg D. Modification of low-density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low-density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984;81:3883-7.
10. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Eng J Med 1989;320:915-24.
11. Steinberg D. Low-density lipoprotein oxidation and its pathological significance. J Biol Chem 1997;272:20963-6.
12. George J, Harats D, Gilburd B et al. Immunolocalisation of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999;99:2277-30.
13. Kobayashi K, Kishi M, Atsumi T et al. Circulating oxidised LDL forms complexes With β2-glycoprotein I: Implication as an atherogenic autoantigen. J Lipid Res 2003;44:716-26.
14. 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997;107:569-73.
15. 2-glycoprotein I mediates autoantibody-dependent uptake of oxidised low density lipoprotein by macrophages. J Lipid Res 2001;42:697-709.
16. 2-glycoprotein I and mediate antibody-dependent uptake of oxidised LDL by macrophages. J Lipid Res 2002;43:1486-95.
17. Alves J, Ames P, Donohue S et al. Antibodies to high-density lipoprotein and β2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002;46:2686-94.
18. Nicolo D, Goldman B, Monestier M. Reduction of atherosclerosis in low-density lipoprotein receptor-deficient mice by passive administration of antiphospholipid embody. Arthritis Rheum 2003;48:2974-78.
19. Holers VM, Girardi G, Mo L et al. Complement C3 activation is required for antiphospholipid antibody-induced foetal loss. J Exp Med 2002;195:211-20.
20. Girardi G, Berman J, Redecha P et al. Complement C5a receptors arid neutrophils mediate foetal injury in the antiphospholipid syndrome. J Clin Invest 2003;112: 1644-54.
21. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced foetal loss by inhibiting complement activation. Nat Med 2004;10:1222-6.
22. Papamichael CM, Lekakis JP, Stamatelopoulos KS et al. Ankle-brachial index as a predictor of the extent of coronary atherosclerosis and cardiovascular events in patients with coronary artery disease. Am J Cardiol 2000;86:615-8.
23. Sikkink CJ, Van Asten WN, Vant'Hof MA, Van Langen H, Vander Vliet JA. Decreased ankle-brachial indices in relation to morbidity and mortality in patients with peripheral arterial disease. Vasc Med 1997;2:169-73.
24. Zheng ZJ, Sharrett AR, Chambless LE et al. Associations of anide-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 1997;131:115-25.
25. Mckenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991;87:119-28.
26. Tsai AW, Folsom AR, Rosamond WD, Jones DW. Ankle-Brachial Index and 7-year ischaemic stroke incidence. The ARIC study. Stroke 2001;32:1721-4.
27. Dolan ND, Liu K, Criqui MH et al. Peripheral artery disease, diabetes, and reduced lower extremity functioning. Diabetes Care 2002;25:113-20.
28. Baron MA, Khamashta MA, Hughes GRV, D'Cruz DP. Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 2005;64:144-6.
29. Christodoulou C, Zain M, Bertolaccini ML et al. Prevalence of an abnormal ankle-brachial index in patients with antiphospholipid syndrome with pregnancy loss but without thrombosis: A controlled study. Ann Rheum Dis 2006;65:683-4.
30. Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res 2001;89:305-16.
31. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999;340:14-22.
32. Rietzschel ER, DeBuyzere ML, Duprez DA, Clement DL. Interchangeability of carotid and femoral intima media thickness risk stratification. Int Angiol 2001;20:38-46.
33. Belcaro G, Nicolaides AN, Laurora G et al. Ultrasound morphology classification of the arterial wall and cardiovascular events in a 6-year follow-up study. Arterioscler Thromb Vasc Biol 1996;16:861-6.
34. Medina G, Casaos O, Jara LJ et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 2003;62;607-10.
35. Charakida M, Halcox JP, Sangle S et al. Endothelial dysfunction and increased carotid intima media thickness in primary antiphospholipid syndrome. Rhematology 2006;45(Suppl.1):i167. Abstract.
36. Mercanoglu F, Erdogan D, Oflaz H et al. Impaired brachial endothelial function in patients with primary antiphospholipid syndrome. Int J Clin Pract 2004;58:1003-7.
37. Stalc M, Poredos P, Peternel P, Tomsic M, Sebestjen M, Kveder T. Endothelial function is impaired in patients with primary antiphospholipid syndrome. Thromb Res 2006;118:455-61.
38. Vlachoyiannopoulos PG, Kanellopoulos PG, Ioannidis JPA, Tektonidou MG, Mastorakou I, Moutsopoulos HM. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: A controlled study. Rheumatology 2003;42:645-51.
39. Jimenez S, Garcia-Criado MA, Tassies D et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 2005;44:756-61.
40. Sipek-Dolnicar A, Hojnik M, Bozic B, Vizjak A, Rozman B, Ferluga D. Clinical presentations and vascular histopathology in autopsied patients with systemic lupus erythematosus and anticardiolipin antibodies. Clin Exp Rheumatol 2002;20:335-42.
41. Sangle SR, D'Cruz DP, Jan W et al. Renal artery stenosis in the antiphopsholipid (Hughes) syndrome and hypertension. Ann Rheum Dis 2003;62:999-1002.
42. Ben-Ami D, Bar-Meir E, Shoenfeld Y. Stenosis in antiphospholipid syndrome: A new finding with clinical implications. Lupus 2006;15:466-72.
43. Sangle SR, D'Cruz DP, Abbs IC, Khamashta MA, Hughes GR. Renal artery stenosis in hypertensive patients with antiphospholipid (Hughes) syndrome: Outcome following anticoagulation. Rheumatology 2005;44:372-7.
44. Saflan RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001;344:431-42.
45. Sangle SR, Jan W, Lau IS, Bennett AN, Hughes GR, D'Cruz DP. Coeliac artery stenosis and antiphospholipid (Hughes) syndrome/antiphospholipid antibodies. Clin Exp Rheumatol 2006;24:348.
46. Tenedios F, Erkan D, Lockshin MD. Cardiac involvement in the antiphospholipid syndrome. Lupus 2005;14:691-6.
47. Lockshin M, Tenedios F, Petri M et al. Cardiac disease in the antiphospholipid syndrome: Recommendations for treatment. Committee consensus report. Lupus 2003;12:518-23.
48. Vlachoyiannopoulos PG, Samarkos M. Peripheral vascular disease in antiphospholipid syndrome. Thromb Res 2004;114:509-19.
49. Alarcon-Segovia D, Cardiell MH, Reyes E. Antiphospholipid arterial vasculopathy. J Rheumatol 1989;16:762-7.
50. Brey RL, Abbott RD, Curb JD et al. Beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischaemic stroke and myocardial infarction: The Honolulu heart program. Stroke 2001;32:1701-6.
51. Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology 2003;42:200-13.
52. Cervera R, Khamashta MA, Font J et al. High prevalence of significant heart valve lesions in patients with the primary antiphospholipid syndrome. Lupus 1991;1:43-7.
53. Galve E, Ordi J, Barquinero J et al. Valvular heart disease in the primary antiphospholipid syndrome. Ann Intern Med 1992;116:293-9.
54. Erdogan D, Goren MT, Diz-Kucukkaya R, Inanc M. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: A transoesophageal echocardiographic study. Stroke 2005;36:592-6.
55. Provenzale JM, Barboriak DP, Allen NB, Ortel TL. Antiphospholipid antibodies: Findings at arteriography. Am J Neuroradiol 1998;19:611-6.
56. Hughson MD, McCarty GA, Sholer CM, Brumback RA. Thrombotic cerebral arteriopathy in patients with the antiphospholipid syndrome. Mod Pathol 1993;6:644-53.
57. Westerman EM, Miles JM, Backonja M, Sundstrom WR. Neuropathologic findings in multi-infarct dementia associated with anticardiolipin antibody. Arthritis Rheum 1992;35:1038-41.
58. Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-sponsored by the Council an Cardiovascular Radiology and Intervention. Stroke 2006;37:577-617.
59. Ruiz-Irastorza G, Khamashta MA. Stroke and antiphospholipid syndrome: the treatment debate. Rheumatology 2005;44:971-4.